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Abstract
Phase-change contrast agents (PCCAs) for ultrasound-based applications have resulted in novel 
ways of approaching diagnostic and therapeutic techniques beyond what is possible with 
microbubble contrast agents and liquid emulsions. When subjected to sufficient pressures 
delivered by an ultrasound transducer, stabilized droplets undergo a phase-transition to the gaseous 
state and a volumetric expansion occurs. This phenomenon, termed acoustic droplet vaporization, 
has been proposed as a means to address a number of in vivo applications at the microscale and 
nanoscale. In this review, the history of PCCAs, physical mechanisms involved, and proposed 
applications are discussed with a summary of studies demonstrated in vivo. Factors that influence 
the design of PCCAs are discussed, as well as the need for future studies to characterize potential 
bioeffects for administration in humans and optimization of ultrasound parameters.
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INTRODUCTION
The relatively recent concept of designing diagnostic and therapeutic phase-change contrast 
agents (PCCAs) based on an ultrasound triggered phase-transition has provided medical 
researchers with a ‘middle-ground’ between the inert liquid emulsion and gas-based 
microbubble contrast agent (MCA) platforms. PCCAs can be generated in a wide range of 
useful sizes and, once activated, show high echogenicity (Fig. 1). The ability to 
ultrasonically induce activation with temporal and spatial specificity has resulted in the 
emergence of a diverse set of techniques for in vivo and in vitro applications.
Perfluorochemicals and perfluorocarbons (referred to collectively here as PFCs), in both the 
liquid and gaseous state, have proven to be favorable compounds for inert liquid emulsions, 
MCAs, and PCCAs due to their unique properties. When administered in-vivo, liquid 
emulsions of high boiling-point PFCs are inert, non-toxic in small doses, and can have 
relative stability in circulation due to high molecular weight, immiscibility in water, and low 
surface tension [1, 2]. Depending on the choice of PFC, the emulsions may persist stably in-
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vivo for hours to days [3], which is attractive for applications involving gradual 
accumulation at a target site and/or sustained release of drugs. Applications are not strictly 
intra-vascular because liquid PFC emulsions can be generated with a broad range of sizes, 
including the hundred-nanometer range. A number of applications have been proposed, 
including molecular imaging and therapy of thrombi, tumor angiogenesis, and 
atherosclerosis-related diseases [4–8], quantitative in vivo imaging and contrast 
enhancement [1, 3, 9], and cell tracking [10, 11]. The ability to solubilize large amounts of 
gas into liquid PFCs has resulted in the development of oxygen delivery applications that 
may be useful for extending tissue viability during hypoxic events (such as cardiac bypass 
and hemorrhagic shock), enhancement of tumor radiation therapy, and liquid breathing [12–
17]. Although some PFCs exhibit echogenicity due to a lower speed-of-sound and higher 
density than water [18–20], the contrast provided is much lower than that of MCAs. Some 
studies have shown that once bound to a surface, a liquid PFC-core agent can increase the 
acoustic reflectivity of the target, and that the reflectivity may be optimized by the choice of 
PFC [18, 21]. Additionally, liquid PFC-based agents are convenient for multimodal imaging 
beyond ultrasound either through endogenous PFC properties or through the inclusion of 
other agents. PFCs, particularly those with higher boiling points, carry a high number of 
fluorine atoms that can be used for 19F MR spectroscopy [22, 23]. Inclusion of paramagnetic 
nanoparticles, fluorescent nanoparticles, and/or radioisotopes enable these PFC emulsions to 
be extended to 1H MR T1-weighted imaging, SPECT-CT [4, 5, 8, 22, 23], and optical 
fluorescence imaging [10, 11]. Particular PFCs may also serve as radiopaque blood pool 
agents for CT due to the long intravascular half-life [1, 3, 9].
MCAs for diagnostic and therapeutic ultrasound have provided a promising platform for 
addressing a number of issues, including applications in echocardiography, microvascular 
perfusion imaging, thermal ablation enhancement, molecular imaging, drug and gene 
delivery, and thrombolysis [24–41]. PFCs have been favored for the gaseous core for more 
than a decade because of low solubility compared to other gases [42, 43]. MCAs are 
typically produced with diameters in the 1–5 µm range, which is a compromise between 
enabling free passage through capillary beds, and maximizing ultrasound imaging 
sensitivity. When excited by ultrasound energy, highly compressible microbubbles exhibit 
nonlinear behavior. This has led to microbubble-specific imaging modalities that enable 
contrast imaging with high sensitivity and low background signal from tissue [44–50]. 
However, sizes optimal for contrast enhancement limit passage to within the vascular space 
[38], and microbubble persistence in vivo is typically only on the order of minutes [43].
Preclinical studies have suggested that, in contrast to MCAs, PCCAs can be designed to 
have relative stability in circulation prior to ultrasound-induced vaporization. Once 
vaporized, they exhibit contrast enhancement similar to what MCAs provide [51–55]. 
Several reviews on MCAs [35, 56, 57], liquid PFC contrast agents [58], and methods of 
drug/gene delivery [59] have included discussions of PCCAs. In this review, a brief survey 
of the history of phase-change contrast agents and the multiple environmental, design, and 
ultrasound-based factors that influence droplet vaporization is presented. The many 
proposed applications at both the microscale and nanoscale are discussed with a summary of 
the in vivo studies performed to date that show promising results for future use in humans. 
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Issues involved with PCCA design as well as possibilities for future studies and applications 
are addressed.
PHASE-CHANGE CONTRAST AGENTS: HISTORY AND INFLUENCING 
FACTORS
Although the general physics of droplet vaporization has been well-described in the 
literature, phase-transition as a result of ultrasound energy and the range of diagnostic and 
therapeutic possibilities for PCCAs have only begun to emerge in the past two decades. 
Phase-change colloids for ultrasonic imaging were first proposed by Quay in 1996 [60], 
resulting in development of the contrast agent EchoGen™ (Sonus Pharmaceuticals, Inc., 
Bothell, WA), although clinical trials were ultimately discontinued. EchoGen™ was 
fundamentally different in application than most PCCAs being developed currently in that 
stable emulsions of dodecafluoropentane (DDFP) were pre-conditioned to induce phase-
transition into gas-filled contrast agents in the 2 – 5 µm diameter range prior to intravenous 
injection [61–63], rather than activation while in circulation. In 1998, Apfel proposed 
superheated droplets that, while circulating in vivo, could be activated with a degree of 
spatial specificity by ionizing radiation or ultrasound for enhanced diagnostic capability, 
drug delivery, and targeted vessel occlusion [64].
Perfluorocarbons and perfluorochemicals have been particularly attractive compounds in 
conjunction with PCCAs – not only due to the properties stated earlier, but also because 
many have boiling points near physiological temperatures, which allows for the design of 
droplets in or near a superheated state. Table 1 lists selected PFCs that have been used for 
inert liquid emulsions, MCAs, and PCCAs along with their physical properties, if available, 
gathered from several sources of literature [18, 20, 65]. DDFP, in particular, has been the 
most often-used compound because its boiling point of 29°C allows for the possibility of 
droplet generation at room temperature, and exposure to physiological temperatures results 
in a superheated droplet - although in practice, droplet size becomes a factor due to the 
effects of surface tension.
Surface tension plays a large role in both the threshold of vaporization for a droplet and the 
subsequent volumetric expansion. Beyond ambient pressure, a PFC droplet will experience 
an additional Laplace pressure as a result of surface tension effects over a defined radius [53, 
66]:
(Equation #1)
where PInside represents the pressure inside the droplet, POutside represents the pressure 
outside the droplet, σ represents surface tension, and r represents radius. Although liquid 
PFCs have characteristically low interfacial surface tension with air, their hydrophobicity 
may lead to relatively high interfacial surface tension when dispersed in water [67, 68], and 
therefore the pressure exerted on the liquid core at the microscale and nanoscale may reach 
several atmospheres above ambient pressure. Through encapsulation in a lipid or polymer 
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shell, Kandadai and colleagues showed that the interfacial surface tension of DDFP droplets 
may be modified by the choice of emulsifier to provide more favorable properties for 
dispersion in aqueous media [68]. The relationship between the ambient pressure a 
compound experiences and the temperature required to induce phase-transition is 
approximated by the Antoine vapor-pressure equation, which is a derivation of the Clausius-
Clapeyron relation. The Antoine vapor-pressure equation is defined as:
(Equation #2)
where T is the ambient temperature, P is the ambient pressure exerted on the droplet, and A, 
B, and C are experimentally derived constants observed for a particular temperature range. 
The relation shows that as the pressure is raised on the droplet core, the energy (in the form 
of temperature and/or ultrasound) required to induce phase transition increases. Because the 
Laplace pressure is an inverse function of radius, this effect becomes more pronounced for 
droplets in the nanometer range. By ideal gas laws with surface tension included, once a 
PFC droplet is vaporized, the resulting bubble will theoretically expand approximately 3 – 6 
times in diameter, depending on initial droplet size, ambient pressure, and the density of the 
PFC selected [66, 69]. Bubbles resulting from droplets at the nanoscale will experience a 
greater Laplace pressure than those resulting from droplets at the microscale, which will 
serve to compress the gas core to a greater extent. Therefore, expansion of droplets in the 
nanometer range is expected to be less than that of droplets in the micrometer range. As 
droplet size diminishes, the expansion factor will theoretically be dominated by the effect of 
surface tension/Laplace pressure, while the expansion factor for very large droplets 
(negligible Laplace pressure) becomes dominated by ambient pressure (Fig. 2). A recent 
experimental study by Wong and colleagues aimed at elucidating the dynamics of bubble 
evolution suggested that, for micron-sized droplets of dodecafluoropentane, the phase 
transition may occur in stages following the initial vaporization event [70]. Once vaporized, 
the bubbles approached theoretical expansion predictions on a microsecond timescale, 
although this may differ with other PFC selections and encapsulations. Several studies have 
shown in vitro that bubbles may expand beyond ideal gas law predictions due to the influx of 
dissolved gases present in the surrounding media [66, 71, 72]. In theory, this additional 
expansion is likely to be more pronounced for larger bubbles than smaller bubbles, as the 
internal pressure of the gas core due to surface tension is less.
The exact mechanisms that cause a droplet to undergo a phase change as a result of 
ultrasonic energy – termed acoustic droplet vaporization (ADV) – are the subject of much 
discussion in the literature. Because the phase-transition boundary of a pure compound is 
governed by the relationship of temperature and vapor pressure, one hypothesis is that the 
phase-transition occurs due to acoustic heating of the droplet. Were this the sole mechanism, 
then increasing ultrasonic pulse duration should increase the degree of acoustic heating and 
trigger phase-transition of droplets. However, most studies have shown that increasing pulse 
duration at clinically relevant ultrasound frequencies results in no significant decrease in the 
vaporization pressure needed to achieve ADV, unless the duration is on the order of 1 
millisecond or greater [73–76]. For these longer pulse lengths, a decrease in the ultrasound 
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pressure needed to induce vaporization has been observed. Although this may seem to be 
indicative of acoustically-induced heating, Lo and colleagues found that by using shorter 
periodic pulses unlikely to cause heating, but with an equivalent total ‘on-time’ as the longer 
pulses, a similar decrease in required ultrasound pressure resulted – indicating heating may 
not be the primary mechanism at work [74]. Other studies have provided convincing 
evidence that acoustic droplet vaporization may be initiated primarily by mechanical effects 
such as acoustic and hydrodynamic cavitation. Kripfgans and colleagues used high-speed 
optical microscopy to observe droplet deformations due to acoustic pressure, and showed 
that droplets with diameters in the micrometer range vaporized once a deformational 
threshold was reached, independent of original size [77]. More recent studies have shown 
vaporization can be induced independently of inertial acoustic cavitation, which has a 
number of implications for safety in vivo [75, 76].
Although the primary mechanism of ADV has not been completely revealed, a number of 
mathematical and physical models have been developed to simulate various properties of 
droplet vaporization. Ye and Bull have developed several models to describe the possible 
effects of post-vaporization expansion on wall stress to determine potential for damaging 
blood vessels [78, 79]. Other models have investigated the effect of surface tension on 
boiling point elevation, freezing point depression, volumetric expansion, and the oscillatory 
evolution of bubbles [69, 80]. Regardless of the primary mechanism, a large number of 
factors have been shown to influence the ultrasound pressure needed to induce vaporization 
of a droplet. These can be separated into three principle categories: environmental factors, 
droplet design, and ultrasound parameters (Table 2). Many of the applications proposed for 
PCCAs stem from the numerous factors that influence their vaporization.
The stability of circulating PCCAs in vivo is not well-characterized to date, although a few 
studies have suggested that certain PCCAs show greater circulation times than their 
counterpart perfluorocarbon-filled MCAs. Rapoport and colleagues have published several 
in vivo studies using polymer-coated, drug-loaded DDFP nanodroplets suggesting that a 
significant amount of nanodroplets were still in circulation as much as 4–5 hours after 
intravenous injection in mice [52, 53, 81]. When subjecting these droplets to ultrasonic 
energy, a substantial reduction in tumor growth was achieved over controls. Recent studies 
from this group using higher boiling-point perfluorocarbons have suggested that the 
residence time may also be significantly influenced by the design of the encapsulating shell 
[54]. Zhang and colleagues recently published results showing that micron-sized droplets of 
DDFP were able to achieve an equivalent effect when activated 30 minutes after intravenous 
injection in a canine model compared to those activated immediately after injection, 
although they did not test timepoints beyond 30 minutes [55]. In general, it is likely that 
longevity in circulation will be a function of PFC boiling point, design of the encapsulating 
shell, and droplet size, although many preclinical studies are needed to characterize these 
effects in vivo.
PCCA APPLICATIONS
Phase-change contrast agent applications can be roughly divided into two categories – those 
with droplets in the micrometer range and those with droplets in the nanometer range. While 
Sheeran and Dayton Page 5













droplets in both size categories have been proposed as drug delivery agents, droplets at the 
microscale, which are confined to vascular flow, hold unique possibilities for applications 
such as targeted vessel occlusion, ultrasound aberration correction, enhancing cavitation 
activity, and creation of internal markers for intraoperative guidance. Droplets at the 
nanoscale are primarily designed to take advantage of the well-studied enhanced 
permeability and retention (EPR) effect of solid tumors. As tumors grow and recruit new 
vasculature, the rapidly-formed vessels often exhibit a degree of ‘loose’ organization. Inter-
endothelial gaps that normally prevent passage of large molecules into interstitial space are 
characteristically wider depending on tumor type, and can allow for extravasation of 
particles well in to the hundreds of nanometers in size.[86, 87] PCCAs that can take 
advantage of the EPR effect have been proposed for applications such as ultrasound-
mediated drug delivery, diagnostic imaging, and enhanced thermal ablation. In both size 
ranges, droplets can be administered intra-arterially, intravenously, or through direct intra-
tumoral injection and then vaporized [51, 88–90]. In a few cases, the applications proposed 
for nanoscale droplets are similar to those for microscale droplets – such as drug delivery to 
solid tumors and enhancing the effects of HIFU therapy. Future in vivo work will be needed 
to develop an understanding of the tradeoffs inherent in choosing to pursue these techniques 
with microscale vs. nanoscale droplets. The specific applications are discussed below.
Microscale Applications
Vascular Occlusion Agents—Beginning with some of the earliest literature available on 
ADV, there has been significant interest in designing droplets in the micrometer size range 
for the purpose of vessel occlusion [51, 71]. Once vaporized, droplets near 5 µm in diameter 
will result in microbubbles that are on the order of 30 µm – sufficient to occlude 
microvasculature. By using focused ultrasound transducers, vaporization can be induced in 
the feeder arteries of kidneys (and by extension, tumors), resulting in the ability to occlude 
with a high degree of spatial specificity (Fig. 3) [88, 90]. This type of occlusion may be 
especially beneficial in enhancing thermal therapy of tumors, such as in radio-frequency 
ablation. Often the blood supply of the tumor can act as a heat sink - dissipating the heat and 
reducing the efficacy of the treatment. By occluding nearby vasculature, thermal delivery 
may be more successful [88]. Reduced blood flow by occlusion may also be used to induce 
hypoxia in tumors, although future studies will be needed to determine whether the 
influence of PFC oxygen solubility reduces the degree of induced hypoxia in practice [51]. 
ADV-based occlusion appears to provide significant opportunity with regard to drug 
delivery. Residence time of drugs could be increased through reduced blood flow, allowing 
for enhanced diffusion into a targeted region. Drugs may be co-injected systemically or in 
the form of drug delivery vehicles such as liposomes, or alternately could be incorporated 
into the ADV occlusion agent through a dual-phase emulsion or multiple emulsions. Perhaps 
the most promising portrait for the potential of ADV-based occlusion was proffered by 
Fabiilli and colleagues [91]:
1. Through drug-incorporated emulsions, targeted occlusion can coincide 
with release of a chemical embolic agent – thus sustaining embolization.
2. The resulting ischemia may increase the residence time of a therapeutic 
agent locally, enhancing efficacy of therapeutic delivery.
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3. Hypoxia as a result of prolonged ischemia may be useful for activation of 
bioreductive prodrugs – which potentially can be encapsulated in the 
emulsion process.
Although no in vivo validation is available to date, Fabiilli and colleagues have shown 
preliminary in vitro proof-of-concept of encapsulation of thrombin and chlorambucil in 
PCCA emulsions, followed by release with ultrasound-triggered vaporization [91, 92]. These 
studies also demonstrate the need for further optimization of formulation and drug loading 
as well as control over non-US-induced drug release and droplet size prior to preclinical 
studies. How these emulsion techniques perform compared to alternative platforms, such as 
microscale PFC droplets co-injected with drug-loaded liposomes or micelles, will also need 
to be characterized.
Ultimately, the success of ADV-based occlusion techniques depends on the dynamics 
involved in the transport and lodging of microbubbles generated from PCCAs. Due to a 
number of influencing factors, these bubbles may become lodged in the microvasculature 
near the site of vaporization, may slide along the vascular space, or may interact in a 
complex manner with vessel bifurcations downstream. It is also important that the occlusive 
bubbles not be so large as to damage or rupture the vessel wall. Several physical models 
have been developed by the University of Michigan group to simulate these dynamics [78–
80, 93–96]. Although some experimental studies are available on non-ADV microbubble 
embolization [97, 98], further experimental results from ADV-generated microbubbles are 
needed to validate these models as they extend to pulsatile blood flow in the 
microvasculature.
Aberration Correction—Phase aberration of reconstructed ultrasound images is a result 
of cumulative error in estimating the speed-of-sound in the tissue the ultrasonic wave travels 
through. On the transmit side, this leads to the transducer not focusing as desired, and on the 
receive/reconstruction side results in poor, blurry images [51]. Aberration becomes 
especially prominent when imaging through dense tissue or bone – such as the skull, and 
worsens as ultrasound frequency increases. One proposed mechanism for aberration 
correction is to use disperse point targets in the form of echogenic gas bubbles at defined 
locations in the volume-of-interest. Using iterative methods, the ‘brightness’ of the point 
target can be used as a measure of aberration correction, and transducer timing can be 
adjusted to create optimal focusing and image reconstruction. Phase-change contrast agents 
present a unique opportunity for aberration correction in that low-concentration droplets can 
be vaporized with a degree of spatial specificity, lodge in a vessel, and create a stationary 
point beacon for iterative methods [51, 71, 99]. Preliminary results using acoustic droplet 
vaporization have been promising for focusing on transmit (Fig. 4), but have not yet been 
extended to image reconstruction [99].
Cavitation Nucleation Agents—Bioeffects caused by ultrasound-induced cavitation in 
vivo range from cell sonoporation (increasing permeability of the cell wall) to cell lysis and 
tissue homogenization [100]. In addition, beyond certain pressure thresholds significant 
heating can occur [101]. These phenomena can be harnessed for both hyperthermic and non-
thermal tumor treatments – such as cell lysis in combination with enhanced gene 
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transfection due to sonoporation. However, optimal tumor treatment would require precise 
spatial and temporal control of the cavitation events [82]. Cavitation nuclei are relatively 
sparse in blood and tissue, but it has been shown that microbubble contrast agents can act as 
cavitation nuclei and lower the energy needed to induce bioeffects [102–104]. As mentioned 
previously, microbubbles exhibit low circulation times in vivo, and so phase-change contrast 
agents may present a novel means of producing more stable cavitation nuclei with control of 
spatial and temporal activation for therapeutic applications. Early studies by Miller and 
colleagues have shown that hemolysis by lithotripter shock waves was more pronounced in 
the presence of PCCAs in vitro than for MCAs [82]. An in vivo study resulted in enhanced 
cell transfection of DNA plasmids and growth-rate reduction similar to that produced by 
MCAs and macroscopic air bubbles when all were injected intra-tumorally [105]. Lo and 
colleagues proposed that spatial control of droplet vaporization could be used to create 
predictable lesion formation and demonstrated the concept in tissue-mimicking phantoms 
[106]. A recent study by Zhang and colleagues showed that microscale droplets of DDFP 
significantly enhanced lesion formation in vitro as well as in vivo [55]. When droplets were 
introduced to tissue-mimicking phantoms, the exposure time needed to create similar lesions 
as controls was decreased by a factor of 2.5. When equal exposure times were used, the 
average lesion volume was 7-fold greater than phantoms without droplets. In vivo results 
proved even more promising, resulting in a 15-fold increase in volume for lesions formed in 
the canine liver at equal exposure time to controls without droplets.
Internal Markers for Intraoperative Guidance—One of the most recently-developed 
applications for PCCAs involves harnessing their sensitivity to heat and ultrasound pressure 
to create internal markers that may assist during therapeutic or surgical procedures. Huang 
and colleagues proposed a method where PCCAs designed to vaporized at a specific 
temperature are injected near the periphery of a tumor site and activated once the tissue 
reaches a lethal thermal dose - providing real-time feedback on intraoperative ablation 
margins [107]. They demonstrated this concept in vitro using micron-sized PLGA-
encapsulated PCCAs. More recently, Couture and colleagues proposed ‘internal tattooing’, 
where PCCAs loaded with payloads of fluorescent markers are activated to release the 
fluorescent payload at the transducer focus [108]. This could be used to label areas of 
interest and delineate regions preoperatively with a high degree of spatial specificity that 
would then be visible intraoperatively through fluorescence imaging. They demonstrate 
proof-of-concept in vivo by ultrasonically activating PCCAs and labeling tissues at different 
locations in a chicken embryo.
Nanoscale Applications
Intra-tumoral Diagnostics and Therapeutic Delivery—Phase-change contrast agents 
provide a novel means of addressing diagnostics and drug delivery of solid tumors. 
Kawabata and colleagues, who published some of the earliest studies of nanoscale PCCAs 
activated by ultrasound, showed successful vaporization of nanodroplets consisting of 
mixtures of liquid perfluorocarbons [84]. Through the EPR effect, droplets generated in the 
nanometer size range may diffuse out of the vascular space before undergoing phase-change 
triggered by ultrasound. By ideal gas laws with surface tension effects taken into account, 
droplets 200 nm or larger should result in gas microbubbles on the order of 1 µm [66, 69], 
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which would provide significant contrast enhancement of tumor interstitium. This would 
effectively extend microbubble-based imaging beyond the vascular space and create new 
opportunities for tumor detection and treatment. Rapoport and colleagues have proposed a 
multi-faceted imaging and treatment platform using nanoscale PCCAs with drug-loaded 
polymer shells in conjunction with drug-loaded micelles where ultrasound combined with 
droplet vaporization enhances local drug delivery (Fig. 5) [109]. The resulting microbubbles 
(as well as larger secondary bubbles formed by coalescence) can be used as real-time 
delivery confirmation. Over a wide range of studies, her group has demonstrated the promise 
of PCCAs for delivery of paclitaxel and doxorubicin in vitro and in vivo for various cancer 
models using DDFP droplets encapsulated in a polymer shell [52, 53, 81, 89, 109–111]. The 
group has recently begun to explore the use of much higher boiling-point PFCs for increased 
stability, reversible bubble formation, and co-registration with 19F MRI, although they 
conclude that the temporary bubbles observed in the study may be due to gases dissolved in 
the PFC rather than actual vaporization of the PFC itself [54]. Matsuura and colleagues have 
provided promising preliminary evidence that incorporated nanoparticles such as quantum 
dots may act as additional cavitation nuclei within the core, and appear to decrease the 
ultrasound vaporization threshold significantly [85]. They suggest that PCCAs with 
incorporated nanoparticles may offer a means of spatially and temporally controlling 
nanoparticle deposition, and could produce a means to extend ADV-based agents to other 
therapeutic and imaging modalities.
Thermal Ablation Therapy and Therapeutic Bioeffects—PCCAs that have diffused 
into tumor interstitial space could also be used to aid in HIFU tumor ablation or to produce 
therapeutic bioeffects such as those that Miller and colleagues showed for microscale 
droplets. Once vaporized, the resulting bubbles can act as extravascular cavitation nuclei that 
enhance tissue heating and lesion formation from HIFU therapy. Although no published 
studies to date have explored the ability of nanoscale droplets to produce the bioeffects that 
Miller and colleagues observed at the microscale [82, 105], it is possible that nano-PCCAs 
may be similarly used to produce cell lysis, sonoporation, and enhanced gene transfer. 
Zhang and Porter have recently reported on the ability of PCCA nanodroplets to 
significantly enhance thermal delivery in the region of focus once vaporized in gel phantoms 
(Fig. 6) [83]. They suggest that resulting interstitial bubbles in vivo, which would 
theoretically be in the low micrometer range, would have resonance frequencies similar to 
MCAs used in HIFU [112], and therefore would be uniquely suited for tumor ablation and 
lesion formation. Future studies are needed to characterize how interstitial bubbles produced 
by PCCAs interact with the HIFU beam, and the resulting effect on cavitation activities.
Other Applications—Nanoscale PCCAs were used by Mohan and Rapoport to aid in the 
study of intracellular delivery of doxorubicin, including factors that influence penetration 
into the cell nucleus [113]. Their results suggest that ultrasound in the presence of 
microbubbles, including those created by vaporized nanodroplets, transiently permeabilizes 
the cell nucleus and allows penetration of therapeutic drugs into the nucleus. Asami and 
colleagues have also proposed that nanoscale PCCAs could be used to characterize 
viscoelastic properties of tumors by analyzing the waveforms received post-vaporization 
[114].
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When designing phase-change contrast agents, the choice of which PFC comprises the core 
will create inherent trade-offs. As the energy needed to vaporize droplets of a certain size 
increases, the likelihood of inducing unwanted bioeffects for certain applications also 
increases. However, some applications may place a premium on high droplet stability over 
how easily the droplets can be vaporized. The optimal choice of PFC can largely be 
determined by considering:
1. The ideal size-regime of the droplets (nanoscale vs. microscale)
2. The ultrasound frequency used
3. Whether intended for diagnostic or therapeutic ultrasound machines
4. Whether ultrasound-induced bioeffects are acceptable
Droplets in the micrometer range require substantially less ultrasound pressure to induce 
vaporization than droplets in the nanometer range, presumably due to less Laplace pressure 
on the droplet core by interfacial surface tension. Additionally, the pressure required to 
vaporize decreases as the compound boiling point decreases. While increasing the 
ultrasound frequency has been shown to decrease the pressure needed to vaporize, higher 
frequencies will provide less penetration depth into tissues and will therefore limit the ability 
to successfully vaporize droplets in deep-tissue targets. Studies are needed to examine 
optimization of droplet vaporization as a function of frequency for deep-tissue targets in 
vitro and in vivo. For some applications, the ability to vaporize droplets from the lowest 
possible pressures would be ideal. In these cases, the droplets should be made from the PFC 
with the lowest possible boiling point that allows for stable circulation at physiological 
temperatures. For some therapeutic applications, the pressures used are already relatively 
high to create desired bioeffects, and droplets should remain stable until a desired ‘activation 
pulse’ is delivered. For these applications, PFCs with a higher boiling point may be more 
suitable.
Most studies have shown that for applications such as vascular occlusion and aberration 
correction, microscale dodecafluoropentane-based droplets appear to be sufficiently stable 
and are able to be vaporized in vitro at pressures within what diagnostic imaging machines 
typically provide [75, 76], although the pressures used to vaporize in vivo can be much 
higher [90]. DDFP and perfluorohexane (PFH) have been the most commonly-studied PFCs 
for use with nanoscale droplets. At these sizes, the optimal PFC choice is chiefly 
application-dependent. In a study with DDFP nanoemulsions for the purposes of enhancing 
thermal delivery to tumors and creating focal lesions, Zhang and Porter suggest that as the 
temperature rises in tissues, the nanodroplets just outside of the focal region may vaporize 
more easily and lead to unpredictable prefocal lesions [83]. A PFC with a higher boiling 
point, such as PFH, may prove better in this case, as it could still be vaporized and would 
lead to more predictable lesion formation. For co-imaging with 19F MR, a PFC with a higher 
number of Fluorine atoms per molecule may be desirable, although PFCs with more 
Fluorine atoms also have higher boiling points [54].
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For some applications in both the nanometer and micrometer size regimes, it might be 
beneficial for the vaporization to occur at lower pressures than DDFP allows. Diagnostic 
image enhancement of tumors by extravasated nanodroplets requires that the droplets can be 
activated with little to no bioeffects, and by parameters within the range of a clinical imaging 
system. In addition, the degree of drug delivery or vascular occlusion from PCCAs is 
dictated partly by the efficiency of vaporization within the focal region, and so lower 
thresholds may lead to a greater number of vaporized droplets and increased drug delivery 
and/or flow reduction. While these issues may be improved by further optimizing ultrasound 
parameters such as frequency and pulse length, it is also possible to choose PFCs with lower 
boiling points than DDFP. A number of the previously mentioned in vitro studies have 
shown that DDFP droplets have remarkable stability at body temperature, even though the 
bulk boiling point of DDFP is much lower than body temperature. Presumably this is due to 
the increased internal pressure on the compound at the small sizes produced, which 
essentially increases the temperature required to vaporize the droplet. A study by Giesecke 
and Hynynen demonstrated that vaporizing micron-sized albumin-coated DDFP droplets by 
heat alone required temperatures as much as 40°C above the typical boiling point of DDFP 
as a bulk fluid [73], and the difference may increase as droplet size is reduced to the 
nanometer range. This increase in ‘effective boiling point’ leads to the possibility for lower 
boiling-point perfluorocarbons to be explored for PCCAs. This concept has been verified in 
two recent studies showing that decafluorobutane (DFB), which is normally a gas at room 
temperature, can be formed into nanoscale and microscale droplets that are stable in vitro at 
room and body temperature [66, 115]. These droplets can be vaporized at pressures 
significantly lower than similar droplets of DDFP and PFH, which is promising for 
applications requiring low acoustic pressures. Because DFB is a gas at room temperature, 
droplet generation techniques involved methods of condensing the gas at reduced 
temperatures and/or increased pressures. In the first study, droplets were produced by first 
condensing DFB gas at reduced temperatures and then encapsulating the resulting liquid 
DFB in lipid shells by membrane extrusion. The second study demonstrated a technique of 
‘microbubble condensation’ to produce sub-micron droplets where lipid coated, micron-
sized DFB microbubbles were generated via standard agitation techniques and then exposed 
to increased ambient pressure and decreased ambient temperature until condensation of the 
gas core occurred. Once condensed, the volumetric decrease resulted in sub-micron droplets 
that remained stable due to the increased internal pressure. Further studies are needed to 
determine overall in vivo stability of decafluorobutane droplets in both size ranges compared 
to previously explored PFCs, as well as to explore the possibility to stabilize droplets of 
lower boiling-point PFCs such as octafluoropropane.
One additional method of droplet design is to alter the amount of energy needed to vaporize 
a specific droplet by creating a mixture of PFCs with different boiling points. This technique 
was first proposed by Kawabata and colleagues, who demonstrated that mixing DDFP (b.p. 
29°C) and 2H,3H-DDFP (b.p. 53°C) resulted in a droplet that required more energy to 
vaporized than if it contained only DDFP, but less than if it contained only 2H,3H-DDFP 
[84]. This technique could be useful in designing PCCAs for an optimal trade-off between 
stability in circulation and pressure required to induce vaporization.
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Although fewer articles are available for phase-change contrast agents compared to 
microbubbles and inert liquid PFC emulsions, a high proportion of the studies have shown 
promising in vivo results for a variety of animal models and anatomical targets – 
summarized in Table 3. In general, researchers have shown that PCCAs are able to be 
vaporized in vivo to produce desired effects such as reduced blood perfusion and therapeutic 
drug delivery (Fig. 7). In a few instances, droplet-induced bioeffects were observed. An 
early occlusion-based study by Kripfgans and colleagues using a rabbit model showed that 
filtering droplet emulsions to transcapillary sizes (99.99% < 6 µm in diameter) and lowering 
doses to approximately 2×107 droplets/kg eliminated instances of pulmonary hyperinflation 
[88]. They suggest that because the rabbit model may be more susceptible to this bioeffect 
[116], it may be possible to use much higher doses for greater embolization in humans. 
Another occlusion-based study in a canine model by Zhang and colleagues noted instances 
of cardiac arrhythmia and one instance of animal death when droplets (99.6% < 10 µm in 
diameter) were administered in doses on the order of 1×108 droplets/kg to 4×108 droplets/kg 
through an intracardiac method [90]. The effect seemed to stabilize once animals were 
placed on forced ventilation. They hypothesized that these effects were a result of droplets 
occluding a coronary arteriole, inducing ischemia. Although no cardiac arrhythmia was 
observed for intravenous administration, doses approaching 2×109 droplets/kg resulted in 
respiratory distress and changes in blood chemistry. A dose of 3×109 droplets/kg of droplets 
this size (a total perfluorocarbon dose of 0.2 g/kg) was determined to be fatal to the canines. 
In a recent study by Zhang and colleagues aimed at assessing microscale DDFP droplets for 
thermal ablation, a dose of 1.2×108 droplets/kg (99% < 8 µm in diameter) was administered 
intravenously in a canine model and no adverse bioeffects were reported [55]. All other 
studies noted no significant undesired bioeffects. Future studies are needed to optimize 
ultrasonic vaporization in vivo – especially with regard to reducing interference caused by 
respiratory motion in some animals [90].
DISCUSSION
While the in vivo studies mentioned earlier have given ample evidence of the breadth that 
the PCCA platform may provide for future use in humans, more preclinical studies are 
needed to evaluate the potential for bioeffects as a result of PCCA administration. 
Characterizing the chemical effects of PFCs, possibility of vascular damage by very large 
bubbles, stability of agents in circulation, and ultrasound-induced effects from PCCAs 
combined with high pressures and/or pulse lengths will be vital in moving the platform 
toward clinical studies. For applications involving droplets extravasated via the EPR effect, 
the impact of diffusion gradients and uneven interstitial pressure within the tumor on the 
accumulation and delivery of drug payloads requires further investigation [89, 117]. Many 
studies have demonstrated that microscale droplets can be generated in sizes small enough to 
pass through human microvasculature without significant embolization until vaporization is 
induced [73, 76, 88]. To ensure safety while in circulation, further control of the droplet 
upper size limit has been demonstrated through filtering or microfluidic sorting [51, 73, 77, 
106, 118, 119]. Current techniques of droplet generation typically result in polydisperse 
droplet sizes, and so developing new methods to generate monodisperse size distributions of 
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droplets may be useful in that droplets would respond more uniformly in the focal region of 
the transducer – both increasing the efficiency of the technique and reducing the chance of 
unwanted effects. Couture and colleagues demonstrated the use of microfluidics to create 
complex monodisperse PCCAs carrying fluorescent payloads [108]. Recent studies by Martz 
and colleagues [120] and Bardin and colleagues [121] have used microfluidics to generate 
monodisperse, microscale DDFP droplets that remain monodisperse for several weeks in 
storage. When vaporized by acoustic pressure, the droplets exhibit a highly uniform 
response – confirming the primary benefit of the production method. Techniques such as 
these may be advantageous for the future production and commercialization of PCCAs at the 
microscale.
Many possible applications of the PCCA platform await additional exploration:
1. Targeting ligands could be incorporated in the encapsulating shell to 
provide a means of PCCA-based molecular imaging similar to that of 
microbubbles and inert liquid PFC emulsions [33, 122–125], although no 
studies have been performed to date. The effect that incorporated ligands 
may have on in vivo aspects such as stability in circulation and clearance 
by the reticuloendothelial system will also need to be carefully addressed. 
Once vaporized, PCCAs may be manipulated to enhance targeting through 
ultrasound phenomena such as acoustic radiation force [126–128].
2. Studies have shown that lipid-coated microbubbles and liquid 
perfluorocarbon droplets can be internalized into neutrophils, 
macrophages, and tumor cells [129–132]. Kang and colleagues recently 
demonstrated preliminary studies of PCCA uptake into peritoneal 
macrophages followed by acoustic vaporization [133]. The internalization 
of targeted or non-targeted PCCAs into similar cells and subsequent 
vaporization could lead to new methods of tissue-specific treatments.
3. Several of the previously mentioned sources have either suggested or 
given preliminary demonstration of the possibility of co-imaging with CT 
and MR techniques, and through incorporation of nanoparticles this may 
be extended to additional modalities. Strohm and colleagues recently 
showed that incorporation of PbS nanoparticles into micron-sized droplets 
of DDFP allowed the droplets to be vaporized by near-infrared laser 
irradiation due to heat generated by the particles [134]. This may be 
harnessed in the future to develop new techniques in photoacoustic 
imaging
4. PCCAs could be co-injected with other platforms to create novel imaging 
and treatment techniques. Lo and colleagues showed that co-injection with 
MCAs significantly decreased the vaporization threshold for PCCAs by 
enhancing the acoustic field in the vicinity of the droplets [74]. Therefore, 
microbubbles, which could also be targeted for angiogenesis, might be 
useful in reducing the vaporization threshold for extravasated nanodroplets 
and improving drug delivery efficiency. A platform of drug-carrying 
liposomes/micelles and PCCAs could be developed such that the 
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vaporized droplets confirm therapeutic delivery and cavitation-based 
effects from the resulting bubbles enhance release of drugs. Finally, a co-
injection of both nanoscale and microscale PCCAs could create a 
treatment where drugs are simultaneously released in the tumor 
interstitium by extravasated nanodroplets and in the vascular space by 
larger droplets that vaporize to form tissue-occluding microbubbles.
5. The nonlinear acoustic response from microbubbles excited in an 
ultrasound field has been harnessed to create contrast-specific techniques 
which can provide high contrast sensitivity while suppressing tissue 
background [46–50]. Two recent studies have demonstrated that the time-
dependent spectral content of evolving bubbles resulting from vaporized 
PCCAs may have significantly different spectral information than MCAs 
[72, 135], which could lead to further contrast-specific imaging 
techniques.
CONCLUSION
Phase-change contrast agents, which have properties of both the liquid emulsion and 
microbubble platforms, provide a unique set of tools to address in vivo and in vitro 
applications in novel ways. They can be generated over a wide range of useful sizes for 
diagnostic and therapeutic applications and can be manipulated in real-time, noninvasively, 
and with a non-ionizing imaging modality – ultrasound – that provides temporal and spatial 
specificity for droplet activation. In liquid form, they may be designed to exhibit smaller 
sizes and greater stability than MCAs, but once vaporized into microbubbles, result in 
marked contrast enhancement over surrounding tissue.
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Vaporization of PFC droplets as a result of exposure to ultrasonic pulses. Shown here, a 
droplet of dodecafluoropentane encapsulated in a lipid shell is stable in vitro at 37°C, but 
vaporizes upon exposure to a 5 MHz ultrasonic pulse. The phase-transition results in a 
bubble approximately 5–6 times larger (unpublished data).
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Effect of droplet size on expansion factor according to ideal gas laws with Laplace pressure 
included for a selected PFC. Calculations are presented for two variations of both ambient 
pressure (Pin vitro ≈ 101 kPa; Pin vivo ≈ 114 kPa) and surface tension (σ1 = 30 mN/m; σ2 = 51 
mN/m). Expansion of droplets on the order of 10 µm is primarily dependent on ambient 
pressure, while expansion of droplets 500 nm or less is primarily dependent on surface 
tension. Reprinted from Ultrasound in Medicine & Biology, Vol. 37, Sheeran PS, Wong VP, 
Luois S, et al., “Decafluorobutane as a phase-change contrast agent for low-energy 
extravascular ultrasonic imaging”, 1518-30 (2011), with permission from Elsevier.
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PCCA tissue occlusion demonstrated in a canine kidney with droplets injected intravenously. 
Pulse-wave Doppler spectrum taken at the targeted spot in the renal artery before (a) and 
immediately after ADV (b), where blood flow reversal and narrowing of the waveform along 
with significant shadowing in the kidney is observed possibly because of substantial vascular 
occlusion. Reprinted from Ultrasound in Medicine & Biology, Vol. 52, Zhang M, Fabiilli 
ML, Haworth KJ, et al., “Initial investigation of acoustic droplet vaporization for occlusion 
in canine kidney”, 1691–703 (2010), with permission from Elsevier.
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Ultrasound transcranial radiofrequency lines gathered using ex vivo human skulls. 
Misalignment of the peak amplitude of an ADV point beacon due to aberration (top) was 
corrected using time-reversal focusing (bottom). Reprinted from Ultrasound in Medicine & 
Biology, Vol. 34, Haworth KJ, Fowlkes JB, Carson PL, Kripfgans OD, “Towards aberration 
correction of transcranial ultrasound using acoustic droplet vaporization”, 435–45 (2008), 
with permission from Elsevier.
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Schematic representation of passive drug targeting through the defective tumor 
microvasculature using an echogenic drug delivery system. The system comprises micelles 
(small circles), PFC nanodroplets (stars), and PFC microbubbles (large circles). Lipophilic 
drugs can be localized in the micelle cores and in the walls of nanodroplets/microbubbles. 
Tumors are characterized by defective vasculature with large gaps between the endothelial 
cells, which allows extravasation of drug-loaded micelles and small nanodroplets into the 
tumor interstitium. Primary microbubbles are formed from the vaporization of nanodroplets 
due to hyperthermia or ultrasound, and larger microbubbles appear due to coalescence of the 
primary microbubbles. Rapoport N, Gao Z, Kennedy A, “Multifunctional nanoparticles for 
combining ultrasonic tumor imaging and targeted chemotherapy”, J Natl Cancer Inst, 2007, 
Vol. 99, 1095–106, by permission of Oxford University Press.
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Presence of bubbles formed by vaporized DDFP nanodroplets increased the thermal delivery 
by ultrasound to a tissue-mimicking phantom. Temperature elevations were measured during 
a 10-second HIFU exposure with and without an ADV pulse. The function generator was 
switched from continuous to pulse mode to fire the ADV pulse, and then back to continuous 
mode for heat deposition. The switching period led to the temperature drop during that 
period of time. The measured temperature reached a plateau in the presence of vaporized 
nanodroplets, most likely because of shielding effects. Reprinted from Ultrasound in 
Medicine & Biology, Vol 36, Zhang P, Porter T, “An in vitro study of a phase-shift 
nanoemulsion: a potential nucleation agent for bubble-enhanced HIFU tumor ablation”, 
1856–66 (2010), with permission from Elsevier.
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Demonstration of drug delivery by the interaction of ultrasound and drug-loaded 
nanodroplets/micelles. A nu/nu mouse bearing two ovarian carcinoma tumors immediately 
before (A) and 3 weeks after the treatment (B). The mouse was treated by four systemic 
injections of paclitaxel-loaded nanodroplets given twice weekly, while only the right tumor 
was sonicated by 1 MHz continuous-wave ultrasound 4 hours after the injection. The left 
tumor grew at the same rate as the controls, while the right tumor regressed, demonstrating 
paclitaxel release into the tumor volume. Reprinted from J Control Release, Vol. 138, 
Rapoport NY, Kennedy AM, Shea JE, Scaife CL, Nam KH, “Controlled and targeted tumor 
chemotherapy by ultrasound-activated nanoemulsions/microbubbles”, 268–76 (2009), with 
permission from Elsevier.
Sheeran and Dayton Page 28







































































































































































































































































































































































































































Sheeran and Dayton Page 30
Table 2
Relation of Influencing Factors to US Vaporization Threshold
Environmental
Factor Relation to US Pressure Threshold References
Ambient Temp. Inverse [72, 75, 76, 82, 83]
Ambient Pressure Direct Governing Eqs.
Viscosity of Surrounding Medium Direct [71, 75]
Presence of MCAs Inverse [74]
Droplet Design
Factor Relation to US Pressure Threshold References
PFC Boiling Point Direct [66, 73, 75, 84, 85]
Droplet Diameter Inverse [66, 75–77]
Shell Surface Tension Direct [53]
Incorporated Nanoparticles Inverse [85]
Droplet Concentration No Effect or Inverse [72, 83]
Ultrasound Parameters
Factor Relation to US Pressure Threshold References
Frequency Inverse [51, 71, 76]
Pulse Length No Effect or Inverse [72, 74–76, 83]
Pulse Repetition Frequency No Effect or Inverse [74, 75]
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Table 3
In vivo PCCA studies






Up to 34% regional perfusion reduction in






Flow reduction in externalized and non-
externalized kidneys; Instances of cardiac
arrhythmia, respiratory distress, and death






Average organ perfusion reduction of >70%;
Instances of pulmonary hyperinflation









Point beacons for aberration correction






balb/c mice subcutaneousRENCA tumor model





liver HIFU exposure in presence of droplets created15-fold increase in lesion volume [55]
Internal Markers chickenembryo various
Spatial control over release of fluorescent
markers demonstrated [108]





Delivery of paclitaxel and doxorubicin resulted
in substantial tumor growth rate reduction;








Delivery of paclitaxel and doxorubicin resulted
in substantial tumor growth rate reduction;
Eventual tumor re-growth observed with









Intra-tumoral vaporization of nanodroplets




free circulation Biodistribution of quantum dots obtainedthrough histology [85]




Image contrast enhancement within mice











Preliminary biodistribution co-imaging with
19F MR demonstrated
[54]
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